Charles River Laboratories International, Inc.CRLNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -1.08% | -2.71% | +0.59% | -0.49% | -0.83% |
| Gross Profit Growth | -21.93% | -7.86% | +0.95% | -2.93% | +8.31% |
| EBITDA Growth | -126.79% | -16.02% | -7.38% | -5.70% | +0.00% |
| Operating Income Growth | -226.15% | -40.73% | -33.97% | +13.96% | +0.00% |
| Net Income Growth | -215.30% | -62.17% | -41.85% | -20.76% | +0.00% |
| EPS Growth | -215.62% | -61.83% | -39.43% | -17.16% | +0.00% |
| EPS Diluted Growth | -216.57% | -61.54% | -39.08% | -17.29% | +0.00% |
| Weighted Average Shares Growth | -0.34% | -1.48% | -4.66% | -4.24% | -3.76% |
| Weighted Average Shares Diluted Growth | -0.94% | -1.91% | -4.88% | -4.18% | -3.76% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -27.87% | +32.19% | +5.72% | -15.08% | -7.43% |
| Free Cash Flow Growth | -41.28% | +121.45% | +9.90% | -16.34% | -30.06% |
| Receivables Growth | -7.62% | -3.86% | +0.70% | -2.62% | -1.67% |
| Inventory Growth | -26.75% | -19.69% | -19.93% | -10.01% | +7.38% |
| Asset Growth | -8.13% | -7.00% | -4.88% | -6.12% | -5.22% |
| Book Value per Share Growth | -3.44% | -10.94% | -5.52% | -5.97% | -5.01% |
| Debt Growth | -11.17% | -3.01% | -1.83% | -4.65% | +12.54% |
| R&D Expense Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | -0.73% | -4.56% | +12.81% | -10.85% | -4.13% |